A glucocorticoid-FAS axis controls immune evasion during metastatic seeding

Area of Science:

• Oncology
• Immunology
• Cancer Metastasis

Background:

• Metastasis is a leading cause of cancer mortality, particularly in triple-negative breast cancer.
• Disseminated tumor cells (DTCs) must overcome immune surveillance to establish secondary tumors.
• Mechanisms of immune evasion by early DTCs remain poorly understood.

Purpose of the Study:

• To investigate how DTCs evade anti-tumor immunity during early metastatic seeding.
• To identify key molecular pathways involved in DTC immune evasion.
• To explore therapeutic strategies targeting DTC immune evasion.

Main Methods:

• Utilized a triple-negative breast cancer model with a visible antigen and cognate CD8+ T cells.
• Analyzed surviving DTCs for mechanisms of resistance.
• Employed niche profiling with an optimized labeling tool to identify critical pathways.

Main Results:

• Glucocorticoid receptor (GR) activation was identified as a key driver of resistance to CD8+ T cells and natural killer cells in DTCs.
• GR activation represses the FAS-FASL pathway, a crucial cytotoxic mechanism against DTCs.
• Pharmacological GR inhibition combined with immunotherapy significantly reduced metastatic burden and extended lifespan in mice.

Conclusions:

• GR activation represents a specific immune evasion mechanism in DTCs.
• Targeting GR in combination with immunotherapy offers a potential therapeutic strategy to eliminate DTCs.
• This approach may provide a novel treatment avenue distinct from primary tumor therapies.